• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 21st August 2018

Two New Papers on EQ-5D-5L Valuation in Ireland

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland. In Ireland, the importance of health technology assessment has been embraced for some time. National bodies such as the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.

In Ireland, the importance of health technology assessment has been embraced for some time. National bodies such as the National Centre for Pharmacoeconomics and the Health Information and Quality Authority are involved in economic evaluations. The latter publishes guidance on the conduct of evaluations in Ireland and recommends the use of cost-utility analysis as its preferred evaluation type. Until now, however, no national value set for the generation of utility weights has been published for Ireland.

OHE has collaborated with colleagues from NUI Galway and Queen’s University Belfast to develop an Irish value set for the EQ-5D-5L, a widely used measure of health outcome. The value set study was led by Ciaran O’Neill and followed the international standard protocol for EQ-5D-5L valuation studies developed by the EuroQol Group.

Two papers arising from the collaboration have recently been published. The first paper, published in PharmacoEconomics, is a scientific report of the Irish value set study. It provides a detailed description of the methodology, including the use of a hybrid model to analyse preference data elicited via time trade-off and discrete choice experiment tasks. It also presents the value set, explaining that greater disutility was attached to anxiety/depression than to the other four dimensions. Indeed, it appears that people in Ireland attach more importance to anxiety/depression than do people in other countries where similar studies have been undertaken.

The second paper, published in Health and Quality of Life Outcomes, examines how adherence to particular religious beliefs influences attitudes to euthanasia, and how attitudes to euthanasia influences people’s willingness to assign worse than dead (WTD) values to health states. It reports that religiosity was a significant determinant of attitudes to euthanasia, and attitudes to euthanasia were a significant determinant of the likelihood of assigning WTD values. The paper adds to the growing literature on the relationship between religious beliefs and health state values, including qualitative work undertaken by UAE University in collaboration with OHE.

Both papers are available open access. Further outputs from this programme of work will be made available over the coming months.

For more information about OHE’s research on valuing health outcomes, contact Koonal Shah.

Citations

Barry, L., Hobbins, A., Kelleher, D., Shah, K., Devlin, N., Ramos Goñi, J.M. and O’Neill, C., 2018. Euthanasia, religiosity and the valuation of health states: results from an Irish EQ5D5L valuation study and their implications for anchor values. Health and Quality of Life Outcomes, 16(152). DOI

Hobbins, A., Barry, L., Kelleher, D., Shah, K., Devlin, N., Ramos Goñi, J.M. and O’Neill, C., 2018. Utility values for health states in Ireland: a value set for the EQ-5D-5L. PharmacoEconomics. DOI

Related research

Devlin, N., Shah, K., Feng, Y., Mulhern, B. and van Hout, B., 2018. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Economics, 27(1), pp.7-22. DOI | RePEc

Elbarazi, I., Devlin, N.J., Katsaiti, M.S., Papadimitropoulos, E.A., Shah, K.K. and Blair, I., 2017. The effect of religion on the perception of health states among adults in the United Arab Emirates: a qualitative study. BMJ Open, 7, e016969. DOI

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!